The Indian government plans to introduce a production-linked incentive (PLI) program in 2026 to boost domestic manufacturing of GLP-1 drugs, used for treating diabetes and obesity. The anti-obesity medication market is projected to reach $100 billion by 2030, as per Goldman Sachs Research. Major Indian pharmaceutical companies like Sun Pharmaceutical Industries Ltd., Cipla Ltd., and Dr. Reddy’s Laboratories Ltd. are developing weight-loss formulations and generic drugs.
